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A B S T R A C T
Miniaturized devices for the extraction of DNA have been used for assessing genetic material in biological,
forensic and environmental samples. However, the ability to isolate trace amounts of highly fragmented DNA
from biological ﬂuids remains a challenge. The current work reports a microﬂuidic approach that combines on
line a dynamic magnetic extraction procedure with droplet-based digital PCR (ddPCR). This strategy maximizes
the surface area for DNA binding within the chip, in order to capture short DNA fragments, with the possibility of
recovering the puriﬁed samples into picoliter volumes for high sensitivity mutation detection. The application of
this technology to capture circulating cell-free DNA (ccfDNA) from serum samples of cancer patients is de-
monstrated herein, with eﬃciencies comparable to standard column-based DNA extraction methods. This
technology uses lesser amounts of required material and reagents, and has a higher potential for automation and
multiplex DNA analysis. Furthermore, this approach can also be extended for the detection of other circulating
biomarkers, such as nucleic acid sequences with aberrant methylation patterns or miRNA.
1. Introduction
The study of circulating tumor DNA (ctDNA) released in the per-
ipheral blood during tumor cell death has emerged as a promising al-
ternative to invasive tissue biopsies [1]. It provides genetic and epige-
netic information similar to that of the primary tumor [2], and its non-
invasive nature, via a simple venal puncture, allows real-time mon-
itoring of tumor burden and treatment response [3–6]. Microﬂuidic-
based technologies such as targeted next generation sequencing (NGS)
and droplet-based digital PCR (ddPCR) are currently being developed
for the highly sensitive detection and quantiﬁcation of ctDNA [7–10].
However, their performance is still limited by pre-analytical steps
performed prior to DNA analysis (e.g., sample collection and DNA
extraction procedures) [3,11,12]. Indeed, it remains challenging to
isolate eﬃciently ctDNA from blood, due to the very low concentration
(typically few ng/mL), and high fragmentation (in the 50–1000 bp size
range) of these molecules, in particular at early stages of cancer [3,11].
More eﬃcient isolation methods are thus needed for the use of ctDNA
as a non-invasive cancer biomarker.
Sample pre-treatment usually involves time consuming procedures
with manual pipetting and numerous centrifugation steps that could
increase the potential sources of error, DNA loss and sample con-
tamination [13]. Developing miniaturized procedures for DNA isolation
can help simplifying the process and interfacing with downstream
analysis modules. Reducing the volumes of samples and reagents re-
quired per test can also be beneﬁcial when only low amounts of samples
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are available (e.g. ﬁne needle aspirates). A variety of microﬂuidic de-
vices has been developed for the solid-phase extraction of nucleic acids
[13,14], but only few studies have focused on the puriﬁcation of cell-
free DNA from biological samples [15–17]. Microdevices employing
silica chemistries (based on previous developments for standard spin
column procedures) have been used for the isolation of DNA from pre-
puriﬁed samples or concentrated genomic DNA from blood samples
(> 1 ng/μL), showing extraction eﬃciencies ranging from 45 to 70%
[18–21]. However, silica-based technologies have been limited by the
need of chaotropic salts for eﬃcient DNA binding to the silica surface,
and the use of several alcohol washing steps that can inhibit PCR re-
actions. In contrast, electrophoretic [15] or electrostatic-based ap-
proaches (e.g. those employing surface chemical treatments with a pH-
induced DNA binding eﬀect) [22–24] have the capability to operate in
an all-aqueous environment, and would thus facilitate the downstream
analysis of the extracted molecules. To increase the surface area for
DNA interaction, paramagnetic microparticles have been implemented
as solid supports for the capture of nucleic acids in microﬂuidic devices
[21,25–27], allowing for the in situ manipulation of particles (suspen-
sion and collection) via external magnets [28,29]. Their surface can
also be functionalized with charge switchable amine-terminated groups
to capture negatively charged DNA by electrostatic interaction [30,31].
We have previously reported the use of a miniaturized ﬂuidized bed
with functionalized paramagnetic particles for the detection of trace
amounts of bacteria from complex samples [32]. We standardized the
microﬂuidic geometry to control the recirculation of microparticles
inside a diamond-shaped microﬂuidic chamber, and maximize the
binding aﬃnity to the solid support [33]. Using an external magnetic
source and a ﬂow control module we can actively adjust the porosity of
the bed of beads, with a global balance between hydrodynamic drag
and magnetic forces (Fig. 1). This approach allowed processing im-
portant volumes of samples in reduced times (> 1 μL/min) while
avoiding clogging artifacts, and providing low backﬂow pressure, as
well as an important surface area for analyte interaction [34].
Here, we developed a microﬂuidic Magnetic ExTRactiOn procedure
(METRO) for eﬃcient DNA isolation using the ﬂuidized bed, allowing
to process raw biological samples, such as undiluted serum, and deliver
concentrated and inhibitor-free eluted DNA samples for downstream
analysis. Our strategy relies on the combination of a ﬁrst module for the
selective capture of all DNA sequences present in the sample (mutant
and wild type) with a second emulsiﬁcation module for the compart-
mentalization of extracted molecules into millions of picoliter droplets
for high-resolution genetic testing by ddPCR. This digital approach
provides high sensitivity and speciﬁcity to distinguish the proportion of
mutant ctDNA in circulating cell-free DNA (ccfDNA, naturally present
in the blood). During the ﬁrst phase of this study, we used synthetic and
genomic DNA samples for the characterization of the diﬀerent steps of
METRO. We then demonstrated the compatibility of our system with
DNA ampliﬁcation for the detection of low concentrated target mole-
cules in serum, using a commercial ddPCR system. We applied these
developments to the extraction and detection of circulating DNA from
the blood of breast and colon cancer patients, and confronted our re-
sults with conventional column-based extraction procedures in a blind
protocol. Finally, we demonstrated the direct coupling of the minia-
turized DNA extraction procedure with ddPCR on chip.
2. Materials and methods
2.1. Microﬂuidic device fabrication and experimental setup
The Cyclic oleﬁn copolymer (COC, Topas® 8007, Topas Advanced
Polymers, Extrusion Lab, Frankfurt, Germany) microﬂuidic devices
were fabricated by hot embossing and sealed using a solvent assisted
bonding method, as described earlier [35,36]. Channel walls were
treated with Pluronic F127 (1 wt% in water, Sigma Aldrich, St. Louis,
MO, USA) to prevent nonspeciﬁc adsorption of particles or DNA mo-
lecules [35]. An inverted microscope (Nikon Ti Eclipse) equipped with
a cooled CCD camera (CoolSNAP HQ2, Photometrics, Roper scientiﬁc-
Princeton instruments) was used for optical inspection and ﬂuorescence
analysis. Pressure and ﬂow rate were controlled using a pressure con-
troller and a ﬂow sensor (Fluigent, France).
2.2. DNA and serum samples
200 bp dsDNA PCR products were produced using ﬂuorescently la-
beled Forward and Reverse primers (EuroFins, Ebersberg, Germany,
Appendix A Supplementary material Section 1.1, Fig. S1 and Table S1).
DNA from the HT29 cancer cell line (ATCC, Manassas, VA, US) was
fragmented with S220 sonicator (Covaris, Woburn, MA, USA) (Fig. S2).
DNA fragment sizes were measured using the LabChip® GX/GXII Mi-
croﬂuidic system (Perkin-Elmer, MA, USA) with the DNA assay 5 K
reagent kit (Perkin-Elmer) and using the 2100 Bioanalyser (Agilent,
Santa Clara, CA, USA) with the DNA 12,000 Kit (Agilent). A Qubit 2.0
ﬂuorometer (Invitrogen, ThermoFisher Scientiﬁc) with the dsDNA HS
Fig. 1. Schematic of the setup for METRO using the micro-
ﬂuidic ﬂuidized bed (a-i). Micrographs of the ﬂuidized bed
before (a-ii) and during (a-iii) sample perfusion on chip.
Magniﬁed view showing the recirculation of beads.
Fluorescence micrographs showing DNA-beads interaction
inside the ﬂuidized bed, before (b-i), during (b-ii), at the end
of DNA capture step (b-iii), and after DNA elution (b-iv). Scale
bars: 500 μm.
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Assay (Invitrogen) was used to measure DNA concentrations. Serum
samples from 10 healthy male donors (Biological Specialty Corporation,
Colmar, US), were pooled, centrifuged at 3000 rpm, and aliquoted for
storage at −80 °C. A new aliquot was thawed and centrifuged at
5000 rpm for 15min prior to each experiment. 7 archived serum sam-
ples from cancer patients, were retrospectively chosen based solely
upon the identiﬁcation of a potential target mutation in a biopsy from
the primary tumor.
2.3. DNA extraction
The procedure for batch extraction of DNA from serum samples was
adapted from the protocol provided by the manufacturer
(ChargeSwitch® gDNA Mini Tissue Kit, Life Technologies, Carlsbad,
CA), using the minimal volumes and number of particles that preserved
the extraction eﬃciency and reproducibility of the protocol. We min-
iaturized the batch extraction procedure to implement the METRO
protocol on chip (Appendix A Supplementary material Section 1.2 and
Table S2). Brieﬂy, we injected binding buﬀer into the COC device and
used a NdFeB12 permanent magnet (30×20×20mm, N50,
ChenYang Technologies, Germany) for loading and manipulating
magnetic microparticles inside the capture chamber (25 μg of particles,
850–900 nm in diameter equivalent to a surface area of 0.1–0.2mm²),
as described earlier [32]. The porosity of the bed was tuned, from
highly packed to disperse particles, by simply controlling the ﬂow rate
inside the chip (up to 1 μL/min), while the position of the external
magnetic source remained constant (Fig. 1a-i,ii,iii). Samples were in-
cubated with lysis buﬀer (with RNAse and Proteinase K) for 1 h at room
temperature, prior to injection. Following the addition of low pH
binding buﬀer (pH < 6), samples were perfused through the expanded
ﬂuidized bed for DNA capture (30–60 μL of sample at 0.4–0.5 μL/min).
After a washing step (15–30 μL of wash buﬀer at 0.5–1 μL/min), DNA
was eluted (5–15 μL of elution buﬀer at 0.2–1 μL/min) and collected for
DNA quantiﬁcation (pH > 8.5).
2.4. Picoliter ddPCR analysis
The extracted DNA was quantiﬁed using the RainDrop Digital PCR
System (Raindance Technologies, Billerica, US) for DNA emulsiﬁcation
and droplet ﬂuorescence read-out [37], with ddPCR assays developed
earlier [38]. Emulsions were thermal cycled on a C1000 Touch Thermal
Cycler (Bio-rad, Hercules, CA, USA). For the integrated extraction and
emulsiﬁcation procedure on chip, we measured the end-point ﬂuores-
cence signal from each droplet using the RainDrop dPCR Sense after
DNA ampliﬁcation. Data were analyzed using the RainDrop Analyst
software as described by the manufacturer.
3. Results and discussion
3.1. DNA extraction capabilities on chip
3.1.1. Miniaturized DNA extraction procedure
Extraction using ChargeSwitch® beads follows three main steps: A)
binding of negatively charged nucleic acids to the positively charged
surface of the beads, B) washing to remove non-speciﬁcally bound
molecules, and C) elution of DNA from the beads. We ﬁrst qualitatively
assessed the behavior of the ﬂuidized bed during these steps using
ﬂuorescently labeled dsDNA (Fig. 1b). Prior to sample perfusion, the
bed of beads was ﬂuidized by ﬂowing binding buﬀer to equilibrate the
surface charge of particles, and homogenize their density in the dia-
mond-shaped chamber (Fig. 1b-i). During step A, the DNA sample was
injected, resulting in a rapid increase in the ﬂuorescence intensity at the
surface of the beads, verifying that ﬂuorescent DNA molecules were
captured. The ﬂuorescence signal was higher in the center of the ﬂui-
dized bed at the beginning of the capture step, and all particles were
covered with ﬂuorescent DNA molecules by the end of the process
(Fig. 1b-ii,iii). This redistribution of the ﬂuorescent signal across the
chamber was driven by the sideward recirculation of magnetic particles
during the ﬂuidization regime (Fig. 1a-iv, Video S1) [33], and was
crucial for maximizing the DNA capture capacity of the device. During
step B, a continuous recirculation of the bed of beads with no loss of
particles was observed, enabling eﬃcient removal of proteins and other
inhibitors from the ﬂuidized bed. More importantly, the ﬂuorescence
intensity on the beads did not decrease signiﬁcantly during this step,
indicating no loss of captured material. During step C, an immediate
decrease in the ﬂuorescence signal at the surface of the particles was
observed, to a level comparable to the initial low auto-ﬂuorescence
from the beads (Fig. 1b-iv), demonstrating the eﬀective ﬂow-through
elution of DNA without the need for an incubation step. We could thus
expect that the amount of DNA remaining on the surface of the particles
at the end of the procedure was very low (at least not detectable by
ﬂuorescence measurements).
We then evaluated the selectivity of our system regarding DNA size,
by capturing and eluting fragments with varying lengths
(100 bp–3000 bp). We observed through microchip gel electrophoresis
analysis that the injected and eluted samples presented the same size
distribution with the same relative peak areas (Appendix A
Supplementary material Section 1.3, Table S3 and Fig. S3), showing the
possibility to isolate fragmented DNA molecules with no preferential
selection of a particular size.
3.1.2. DNA binding capacity using model DNA samples
To quantify the capture eﬃciency of METRO, we perfused diﬀerent
volumes of sample containing ﬂuorescently labeled dsDNA in PBS
buﬀer (200 bp in length, MW=129,000 g/mol, and [C]= 11 ng/μL).
To evaluate the amount of captured DNA in real time, we assessed the
level of ﬂuorescence intensity from the sample in the outlet channel
(Fig. 1a-i): 1) before injecting the beads, and 2) during the DNA capture
process (Appendix A Supplementary material, Section 1.4). We mea-
sured a DNA capture rate higher than 97% for samples with up to
200 ng of DNA, with a slight decrease in capture rate for 300 ng of DNA
(89 ± 8%), probably due to saturation eﬀects and steric repulsion from
DNA molecules captured on the surface of the beads (Fig. 2a). We ob-
served a linear capture rate for DNA inputs in the 0–250 ng range (Fig.
S4), demonstrating the capabilities of our system for the eﬃcient ex-
traction of dsDNA fragments in ideal conditions (i.e. using an aqueous
matrix). We estimated the DNA binding capacity of our system to be at
least in the order of 10 μg of DNA/mg of beads; placing our system in
the higher end of the 5–10 μg of DNA/mg range expected from the
supplier, using the batch procedure recommended for the ChargeS-
witch® particles, and well above the capacity for other commercially
Fig. 2. Capture rates for METRO measured for diﬀerent DNA inputs using
ﬂuorescently labeled dsDNA spiked in (a) PBS and (b) human serum samples
from healthy donors.
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available particles [22].
3.1.3. DNA extraction from human serum
To evaluate the eﬀect of the sample matrix on DNA binding aﬃnity,
we processed human serum samples from healthy donors, spiked with
diﬀerent amounts of ﬂuorescent dsDNA. We measured a capture rate
higher than 63% for samples containing up to 100 ng of DNA and a
stabilization of the capture eﬃciency around 50% for higher amounts
of DNA (48 ± 6% for 200 ng) (Fig. 2b). As expected, we observed a
lower capture rate when using undiluted serum as a matrix, as com-
pared to DNA samples in PBS, which could be related to non-speciﬁc
adsorption of serum proteins (e.g., albumin) or other nucleic acids (e.g.,
ccfDNA or miRNA from serum) to the beads surface through electro-
static interactions [11,39]. The high molecular content of complex
matrices such as human serum or plasma has indeed limited the im-
plementation of microﬂuidic DNA isolation procedures. One approach
to avoid potential screening eﬀects or clogging artifacts during the
isolation process has been to dilute the samples prior to their injection
on chip (10–100-fold) [18,22]. However, such approach is not suitable
for the analysis of ctDNA, as it would radically limit sample processing
capabilities, as well as the sensitive detection of rare events. In this
work, the capture rate for DNA samples in serum is still particularly
high considering the use of undiluted human serum, the small size of
extracted DNA molecules, and the electrostatic-based (thus non-spe-
ciﬁc) nature of the DNA binding strategy.
To estimate the global extraction eﬃciency (including elution) for
the spiked serum samples on chip, we collected the eluted DNA for oﬀ-
chip quantiﬁcation (Qubit® assay, Fig. S5). For an input of 200 ng of
DNA using METRO, we obtained an average extraction eﬃciency of
64 ± 9% (n=5), in the same range as the capture rate for 200 ng
measured above using continuous ﬂuorescence measurements on chip.
We thus expect that all DNA captured inside the ﬂuidized bed was ef-
ﬁciently eluted (i.e. no detectable DNA remaining at the surface of the
beads). In comparison to the batch ChargeSwitch® procedure, the elu-
tion volume on chip was reduced by at least 15-fold (the volume of the
microﬂuidic chamber is 0.65 μL), while maintaining a similar extraction
eﬃciency (Fig. S5).
Other groups have demonstrated the interest of electrostatic-based
approaches for DNA isolation on chip. Nakagawa et al. used an amino
silane-coated microchip to obtain 60% capture and 45% elution rates
for λ-DNA (2 ng/μL) [23]. However, their recovery ratio decreased to
27–40% when extracting human genomic DNA from whole blood, due
to the competitive binding of negatively charged proteins, as demon-
strated here. More recently, Gan et al. developed an original approach
combining a chitosan-modiﬁed ﬁlter paper inside a microﬂuidic device
for DNA extraction [24]. Although they obtained a 62–89% capture
eﬃciency using λ-DNA (with concentrations from 0.05 to 1 ng/μL),
only 8.9–11.5% of the captured DNA could be eluted, thus limiting the
possibility of interfacing with downstream analysis modules. Finally,
non-commercial chitosan-coated magnetic particles have also been
used for eﬃcient DNA isolation, providing high stability, pH tunability
and yield (52 μg from 3mL human saliva), but their implementation on
chip has not been demonstrated [31]. Our technology provides similar
or better DNA extraction eﬃciencies to those reported in the literature
with the added advantages of a higher binding capacity, as well as a
higher potential for scalability and integration with DNA detection and
quantiﬁcation techniques, such as droplet-based digital PCR, as shown
in the following sections.
3.2. Processing biological samples
3.2.1. Quantiﬁcation of DNA extraction eﬃciency by ddPCR
To evaluate the eﬃciency of METRO using more realistic samples
and demonstrate its compatibility with ddPCR analysis (RainDrop
Digital PCR System), we processed undiluted serum from healthy do-
nors spiked with cancer cell line DNA, with fragment size lengths and
concentrations relevant to ctDNA analysis (from 50 to 1,100 bp and
[C]=0–357 ng/mL, Fig. S2) [40]. To diﬀerentiate between spiked
mutant DNA (MUT) and non-mutated ccfDNA (wild type, WT, initially
present in serum samples), we used a mutation speciﬁc assay containing
allele-speciﬁc hydrolysis probes (TaqMan™ probes targeting the R273H
mutation in the TP53 gene). We ﬁrst evaluated the levels of WT DNA for
non-spiked samples, and detected an average concentration of
23 ± 11 ng/mL (equivalent to 7045 ± 3315 copies in 1mL of serum,
n=11), in line with concentrations of ccfDNA previously described for
healthy donors [11]. We observed no false positives or MUT events in
the healthy test samples (Fig. 3a). We then extracted the diﬀerent
spiked samples, and used the digital quantiﬁcation to compare the
number of expected vs. extracted MUT and WT genomes for each
sample (Fig. 3b). We established a calibration curve for the MUT gen-
omes (Fig. 3c) and observed a linear capture/elution relationship for
the diﬀerent input mutant DNA with an overall 37% extraction and
detection eﬃciency. In parallel, we performed the extraction of the
same spiked samples using the ChargeSwitch® procedure in batch.
However, the analysis of eluted DNA from the bench-top protocol did
not generate consistent ddPCR results, probably due to the presence of
inhibiting reagents or molecules still present in the eluent (Fig. S6).
METRO allowed for a more eﬃcient washing process and buﬀer ex-
change inside the microﬂuidic device, thus delivering inhibitor free
samples compatible with ddPCR analysis. These results demonstrated
that our system allows analyzing MUT DNA fragments in concentra-
tions as low as 3 ng/mL of serum in a background of WT DNA (leading
to a mutational ratio of about 10% when considering the amount of WT
ccfDNA in serum samples), using a minute amount of sample (60 μL).
Fig. 3. Detection of R273H TP53 mutation in serum samples spiked with mutant HT29 cell line DNA. (a-b) Two dimensional histograms of the digital PCR assay for
the analysis of circulating DNA extracted from healthy donors (a) and from spiked samples (b). Calibration curve (c): Extracted R273H TP53 mutant DNA digitally
quantiﬁed for varying spike in DNA amounts (0.0033 ng/genome copies). MUT probes: FAM, 6- carboxyﬂuorescein; WT probes: VIC, a proprietary dye of Life
Technologies; A.U., arbitrary units.
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3.2.2. Analysis of serum samples from cancer patients
As a proof of concept, we implemented METRO for the detection of
DNA in serum samples from breast (n= 5) and colon (n= 2) cancer
patients with a known somatic variant in tumor tissue (Table S4).
Speciﬁcally, we extracted 60 μL of serum from each of these patients on
chip and quantiﬁed the number of MUT and WT genomes, using ddPCR
assays speciﬁc to each patient [2,38,41]. We performed two extractions
in parallel for each patient sample, using two microﬂuidic devices with
the same operating conditions. The quantiﬁcation results showed con-
centrations of total ccfDNA (WT+MUT) ranging from 0 to 342 ng/mL
of serum (Table S4), in line with previously reported concentrations for
ccfDNA in the serum of cancer patients [11]. We detected the somatic
variant from patient #6 in the serum samples extracted on chip, with a
concentration of 15.45 ng/mL of MUT ctDNA (equivalent of a 47.5%
mutational ratio for the G12D mutation in the KRAS gene). We con-
sidered this sample as positive for ctDNA, since the concentration was
higher than the limit of detection determined above for spiked serum
samples (Fig. 4b,c and Table S4). We also noticed that patient #1
presented a high concentration of WT DNA but no detectable MUT
ctDNA in serum (Fig. 4a,c and Table S4), which could be related to an
important background of DNA from non-tumor cells (e.g., leukocytes).
We observed a linear relationship when comparing the total ccfDNA
concentrations obtained on chip and through a standard column-based
protocol, for values above the limit of detection of the microﬂuidic
METRO procedure (Fig. 4c, Table S5, Appendix A Supplementary ma-
terial, Section 1.5).
3.3. Integrated DNA extraction and detection procedure on chip
Finally, we developed an integrated device combining METRO, with
a microﬂuidic module enabling the direct emulsiﬁcation of the eluted
DNA, together with PCR reagents, on chip (Fig. 5a,b). The generated
droplets were collected unto 6 individual tubes and submitted to
thermal cycling for DNA ampliﬁcation (Appendix A Supplementary
material, Section 1.6). We evaluated the number of positive events
(droplets containing ampliﬁed DNA) on each elution fraction through
ﬂuorescence detection on chip (Fig. 5c), and estimated an overall DNA
extraction eﬃciency of 64%. We observed that most eluted DNA was
contained in elution fractions from 2 to 4 (with occupation ratios ran-
ging from 0.3 to 1.5%). Although the amount of DNA in elution frac-
tions 1 and 6 was very low (< 250 pg), it was readily preserved and
ampliﬁed using this integrated procedure. Considering the operating
conditions, the complete DNA extraction and emulsiﬁcation of 30 μL of
sample was performed in less than 2 h (Table S2).
Although a DNA isolation and ampliﬁcation procedure using con-
tinuous ﬂow microﬂuidics and microchambers for sample compart-
mentalization was demonstrated earlier [42], we present in this work
the ﬁrst direct eluent emulsiﬁcation method for picoliter droplet-based
dPCR. This approach enables the generation of millions of individual
compartments for single molecule detection. It also allows for the ef-
ﬁcient elution and ampliﬁcation of all DNA captured at the beads sur-
face and oﬀers the possibility to rationally modify the PCR ampliﬁca-
tion environment for each elution fraction (e.g. emulsiﬁcation with a
variety of primers and probes or using diﬀerent thermal cycling con-
ditions), thus opening the route for multiplex analyses.
4. Conclusion
We have combined on-chip, for the ﬁrst time, a miniaturized DNA
extraction platform with ddPCR. We applied this method for the de-
tection and quantiﬁcation of ctDNA from biological samples.
Speciﬁcally, we isolated fragmented DNA in low concentrations directly
from serum samples from cancer patients and demonstrated the com-
patibility of our system with sensitive DNA ampliﬁcation methods, such
as ddPCR. As compared to conventional column-based methods, this
approach has the ability to perform both sample preparation and DNA
detection in a single device, providing comparable results but using
only a few microliters of sample, which could be of great interest for the
implementation of minimally invasive cancer diagnostic procedures.
Furthermore, the METRO procedure oﬀers a high degree of ﬂexibility in
terms of size, number and surface functionalities of the magnetic par-
ticles that can be implemented (e.g. to selectively capture mRNA,
microRNA, methylated DNA sequences, as well as bacterial or viral
DNA).
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extraction using the microﬂuidic METRO procedure and standard column-base protocol. MUT probes: FAM, 6- carboxyﬂuorescein; WT probes: VIC, a proprietary dye
of Life Technologies; A.U., arbitrary units.
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Appendix A. Supplementary data
Supplementary material related to this article can be found, in the
online version, at doi:https://doi.org/10.1016/j.snb.2019.01.159.
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